Pharmaceutical composition containing Anti-integrin α11 antibody for treatment or prevention of aging-related diseases

JPWO2023238845A5Pending Publication Date: 2026-06-15

View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office: JP · JP
Patent Type: Applications
Filing Date: 2023-06-06
Publication Date: 2026-06-15

Application Information

Patent Timeline

06 Jun 2023

Application

15 Jun 2026

Publication

JPWO2023238845A5

IPC: A61K39/395; A61P3/10; A61P13/12; A61P43/00; A61P9/10; A61P9/04; A61P9/06; A61P7/02; A61P3/06; A61P9/12; A61P19/02; A61P19/10; A61P1/02; A61P1/04; A61P29/00; A61P19/00; A61P25/28; A61P25/16; A61P25/14; A61P25/02; A61P3/04; A61P11/00; A61P11/06; A61P27/02; A61P27/06; A61P27/12; A61P27/10; A61P27/16; A61P21/00; A61P17/00; A61P17/02; A61P1/16; A61P1/18; A61P27/04; A61P35/00; C07K16/18

CPC: A61P43/00; A61P3/10; A61P13/12; C07K16/2842; C07K2317/732; A61K2039/505; A61P37/06; A61P3/12

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

AI Technical Summary

Technical Problem

Current methods for selectively removing senescent cells, which contribute to aging diseases, are hindered by the non-specific expression of surface proteins like DPP4, making it difficult to target these cells effectively.

Method used

Development of a pharmaceutical composition containing an anti-integrin α11 (ITGA11) antibody that induces antibody-dependent cell-mediated cytotoxicity specifically in senescent cells, allowing for their selective removal and potential treatment or prevention of aging diseases.

Benefits of technology

The anti-ITGA11 antibody composition effectively reduces senescent cell levels, as demonstrated by decreased p16 expression and improved renal function in diabetes models, indicating its potential in treating various aging-related conditions.

✦ Generated by Eureka AI based on patent content.

Patent Text Reader

Abstract

The present invention provides a novel pharmaceutical composition that is for treating or preventing aging-related diseases and utilizes the selective removal of senescent cells.　A pharmaceutical composition containing anti-integrin α11 (ITGA11) antibodies as an active component is administered to a subject.

Need to check novelty before this filing date? Find Prior Art